CADE CLARK, MD
Hematology & Oncology Physician · TYLER, TX
Individual Active NPI 1679061907
Medicare payment data Part B · 2024
| Year | Beneficiaries | Services | Submitted | Allowed | Paid |
|---|---|---|---|---|---|
| 2024 | 201 | 33,681 | $2,689,226 | $785,969 | $626,774 |
Top procedures (2024)
| HCPCS | Description | Services | Avg allowed | Avg paid |
|---|---|---|---|---|
| J1453 | Injection, fosaprepitant, 1 mg | 4,500 | $0 | $0 |
| J9271 | Injection, pembrolizumab, 1 mg | 3,800 | $57 | $46 |
| J9144 | Injection, daratumumab, 10 mg and hyaluronidase-fihj | 2,700 | $50 | $40 |
| J9267 | Injection, paclitaxel, 1 mg | 2,309 | $0 | $0 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 609 | $0 | $0 |
| J9041 | Injection, bortezomib, 0.1 mg | 490 | $2 | $1 |
| J2469 | Injection, palonosetron hcl, 25 mcg | 390 | $1 | $1 |
| J1626 | Injection, granisetron hydrochloride, 100 mcg | 230 | $0 | $0 |
| 96375 | Injection of additional new drug or substance into vein | 141 | $15 | $12 |
| Q5111 | Injection, pegfilgrastim-cbqv (udenyca), biosimilar, 0.5 mg | 132 | $141 | $112 |
| J9190 | Injection, fluorouracil, 500 mg | 105 | $3 | $2 |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | 98 | $128 | $102 |
Taxonomy & licensure
| Specialty | Code | Primary | License | State |
|---|---|---|---|---|
| Hematology & Oncology Physician | 207RH0003X | ✓ | T3451 | TX |
| Internal Medicine Physician | 207R00000X | T3451 | TX | |
| Student in an Organized Health Care Education/Training Program | 390200000X | — | — |
Medicare eligibility
- Part B
- Yes
- DME
- Yes
- Home health
- Yes
- Power mobility
- Yes
- Hospice
- Yes
Other Hematology & Oncology Physician providers in Texas
- NPI 1679578389
- NPI 1417954751
- NPI 1730447558
- NPI 1821095266
- NPI 1023056553
- NPI 1033116439
- NPI 1407297385
- NPI 1881666477
See all Hematology & Oncology Physician providers in Texas →
Source: NPPES (public domain) and CMS Medicare Physician & Other Practitioners data. Not affiliated with CMS, NPPES, or any government agency.